

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-21 (canceled)

Claim 22 (currently amended): An isolated polypeptide having at least 80% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 26 (SEQ ID NO:69);
- (b) the amino acid sequence of the polypeptide shown in Figure 26 (SEQ ID NO:69), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 26 (SEQ ID NO:69);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 26 (SEQ ID NO:69) lacking its associated signal peptide; or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209527, wherein a nucleic acid encoding the polypeptide is amplified in lung or colon tumors.

Claim 23 (currently amended): The isolated polypeptide of Claim 22 having at least 85% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 26 (SEQ ID NO:69);
- (b) the amino acid sequence of the polypeptide shown in Figure 26 (SEQ ID NO:69), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 26 (SEQ ID NO:69);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 26 (SEQ ID NO:69) lacking its associated signal peptide; or

(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209527, wherein a nucleic acid encoding the polypeptide is amplified in lung or colon tumors.

Claim 24 (currently amended): The isolated polypeptide of Claim 22 having at least 90% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 26 (SEQ ID NO:69);
- (b) the amino acid sequence of the polypeptide shown in Figure 26 (SEQ ID NO:69), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 26 (SEQ ID NO:69);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 26 (SEQ ID NO:69) lacking its associated signal peptide; or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209527, wherein a nucleic acid encoding the polypeptide is amplified in lung or colon tumors.

Claim 25 (currently amended): The isolated polypeptide of Claim 22 having at least 95% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 26 (SEQ ID NO:69);
- (b) the amino acid sequence of the polypeptide shown in Figure 26 (SEQ ID NO:69), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 26 (SEQ ID NO:69);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 26 (SEQ ID NO:69) lacking its associated signal peptide; or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209527, wherein a nucleic acid encoding the polypeptide is amplified in lung or colon tumors.

Claim 26 (currently amended): The isolated polypeptide of Claim 22 having at least 99% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 26 (SEQ ID NO:69);
- (b) the amino acid sequence of the polypeptide shown in Figure 26 (SEQ ID NO:69), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 26 (SEQ ID NO:69);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 26 (SEQ ID NO:69) lacking its associated signal peptide; or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209527, wherein a nucleic acid encoding the polypeptide is amplified in lung or colon tumors.

Claim 27 (previously presented): An isolated polypeptide comprising:

- (a) the amino acid sequence of the polypeptide shown in Figure 26 (SEQ ID NO:69);
- (b) the amino acid sequence of the polypeptide shown in Figure 26 (SEQ ID NO:69), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 26 (SEQ ID NO:69);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 26 (SEQ ID NO:69) lacking its associated signal peptide; or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209527.

Claim 28 (previously presented): The isolated polypeptide of Claim 27 comprising the amino acid sequence of the polypeptide shown in Figure 26 (SEQ ID NO:69).

Claim 29 (previously presented): The isolated polypeptide of Claim 27 comprising the amino acid sequence of the polypeptide shown in Figure 26 (SEQ ID NO:69), lacking its associated signal peptide.

Claim 30 (previously presented): The isolated polypeptide of Claim 27 comprising the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 26 (SEQ ID NO:69).

Claim 31 (previously presented): The isolated polypeptide of Claim 27 comprising the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 26 (SEQ ID NO:69), lacking its associated signal peptide.

Claim 32 (previously presented): The isolated polypeptide of Claim 27 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209527.

Claim 33 (previously presented): A chimeric polypeptide comprising a polypeptide according to Claim 22 fused to a heterologous polypeptide.

Claim 34 (previously presented): The chimeric polypeptide of Claim 33, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.

Please add the following new claims:

Claim 35 (new): An isolated polypeptide comprising the sequence of SEQ ID NO:69 with conservative amino acid substitutions, wherein the polypeptide is encoded by a nucleic acid that is amplified in lung or colon tumors.

Claim 36 (new): An isolated polypeptide comprising the sequence of SEQ ID NO:69 with 0-10 amino acid additions, deletions, or substitutions, wherein the polypeptide is encoded by a nucleic acid that is amplified in lung or colon tumors.